Development of immunogene therapy using T-cells expressing a chimeric antigen receptor for adult T-cell leukemia

2015 Fiscal Year Final Research Report

• Project/Area Number: 25430155
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Jichi Medical University
• Principal Investigator: Tsukahara Tomonori 自治医科大学, 医学部, 講師 (10362120)
• Co-Investigator(Kenkyū-buntansha): OHMINE Ken 自治医科大学, 医学部, 講師 (90316521)
• Co-Investigator(Renkei-kenkyūsha): MORISHITA Kazuhiro 宮崎大学, 医学部, 教授 (80260321)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 免疫遺伝子療法 / キメラ抗原受容体 / T細胞 / 造血器腫瘍

Outline of Final Research Achievements

We conducted experiments to develop immunogene therapy using T-cells expressing a chimeric antigen receptor (CAR) for the treatment of refractory adult T-cell leukemia (ATL). For targeting ATL cells, CARs consisting of an anti-CADM1 antibody or an anti-CD30 antibody, fused to CD28 and CD3ζ signal domains, were constructed. Normal peripheral blood mononuclear cells were transduced with retroviral vectors containing CARs. CD30-CAR-transduced T-cells were expanded ex vivo, and efficiently lyzed CD30(+) ATL cells lines but not a CD30(-) B-cell line in vitro. These results indicate that CD30-CAR T-cells could be useful in the treatment of ATL.

Free Research Field

癌遺伝子治療学